

## Literatur

- Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyan NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. *J Clin Oncol* (2006) 24: 4441-4447.
- [S3-Guidelines „Exocrine pancreatic cancer“ 2007]. . 2007.
- Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF, Rowland KMJ, Nair S, Tschetter LK & Fitch TR. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. *J Clin Oncol* (2004) 22: pp. 4944-4950.
- Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R & Neoptolemos JP. Current standards of surgery for pancreatic cancer. *Br J Surg* (2004) 91: pp. 1410-1427.
- Almoguer C, Shibata D, Forrester K, Martin J, Arnheim N & Peruchio M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell* (1988) 53: pp. 549-554.
- ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. . 2006.
- Arnoletti JP, Buchsbaum DJ, Huang Z, Hawkins AE, Khazaeli MB, Kraus MH & Vickers SM. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. *J Gastrointest Surg* (2004) 8: p. 960-9; discussion 969-70.
- Bakkevedt K, Arnesjo B & Dahl O. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised multicentre study. *Eur J Cancer* (1993) 29A: pp. 698-703.
- Banu E, Banu A, Fodor A, Landi B, Rougier P, Chatellier G, Andrieu J, Oudard S. Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. *Drugs Aging* (2007) 24: 865-879.
- Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG & Benson AB3. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. *J Clin Oncol* (2002) 20: pp. 3270-3275.
- Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santquilani M. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EURO-CARE-4 study. *Lancet Oncol* (2007) 8: pp. 773-783.
- Bozzetti F, Gavazzi C, Mariani L & Crippa F. Glucose-based total parenteral nutrition does not stimulate glucose uptake by humans tumours. *Clin Nutr* (2004) 23: pp. 417-421.
- Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JAC. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. *Br J Cancer* (2002) 87: 161-167.
- Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nisticò C, Terzoli E, Cognetti F, Giannarelli D. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. *Cancer* (2007) 110: 525-533.
- Britten CD, Rowinsky EK, Soignet S, Patnaik A, Yao SL, Deutsch P, Lee Y, Lobell RB, Mazina KE, McCreery H, Pezzuli S & Spriggs D. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. *Clin Cancer Res* (2001) 7: pp. 3894-3903.
- Büchler P, Reber HA, Eibl G, Roth MA, Büchler MW, Friess H, Isacoff WH & Hines OJ. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. *Int J Oncol* (2005) 27: pp. 1125-1130.
- Bydder S & Spry N. Chemotherapy for pancreatic cancer. *N Engl J Med* (2004) 350: p. 2713-5; author reply 2713-5.
- Caraceni A & Portenoy RK. Pain management in patients with pancreatic carcinoma. *Cancer* (1996) 78: pp. 639-653.
- Chaufert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P & Bedenne L. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. *Ann Oncol* (2008) 19: pp. 1592-1599.
- Cress RD, Yin D, Clarke L, Bold R & Holly EA. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). *Cancer Causes Control* (2006) 17: pp. 403-409.
- Cunningham D, Chau I & Stocken CEA. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. *ECCO* (2005) : p. abstr. PS11.
- Cunningham DEA. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. *ECCO 2005*; abstr PS11.
- De Wys W, Begg C & Lavin PEA. Prognostic effects of weight loss prior to chemotherapy in cancer patients. *Am J Med* (1980) 69: pp. 491-497.
- DGEM. Leitlinie Parenterale Ernährung der Deutschen Gesellschaft für Ernährungsmedizin, Nichtchirurgische Onkologie. *Aktuell Ernähr Med* (2007) 32, suppl. 1: pp. 124-133.
- Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V & Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clin Cancer Res* (2008) 14: pp. 4491-4499.
- Dugan MC, Dergham ST, Kucway R, Singh K, Biernat L, Du W, Vitkevicius VK, Crissman JD & Sarkar FH. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. *Pancreas* (1997) 14: pp. 229-236.
- E. Poplin, D. E. Levy, J. Berlin, M. Rothenberg, D. Cella, E. Mitchell, S. Alberts, A. Benson, iii. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). *Journal of Clinical Oncology*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: LBA4004 (2006) : .
- Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, Koorstra JM, Habbe N, Karikari C, Mullendore M, Gabrielson KL, Sharma R, Matsui W & Maitra A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. *Mol Cancer Ther* (2008) 7: pp. 2725-2735.
- Fountzilas G, Bobos M, Kalogera-Fountzila A, Xiros N, Murray S, Linardou H, Karayannopoulou G, Koutas AK, Bafaloukos D, Samantas E, Christodoulou C, Economopoulos T, Kalogeras KT & Kosmidis P. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. *Cancer Invest* (2008) 26: pp. 784-793.
- Frederix E, Soeters P & Wouters EEA. Effects of different tumor types on resting energy expenditure. *Cancer Res* (1991) 51: pp. 6138-6141. [31]
- Friss H, Yamanaka Y, Kobrin MS, Do DA, Büchler MW & Korc M. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. *Clin Cancer Res* (1995) 1: pp. 1413-1420.
- Frolov A, Schuller K, Tzeng CD, Cannon EE, Ku BC, Howard JH, Vickers SM, Heslin MJ, Buchsbaum DJ & Arnoletti JP. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. *Cancer Biol Ther* (2007) 6: pp. 548-554.
- Gilmer-Hill HS, Boggan JE, Smith KA, Frey CF, Wagner FCJ & Hein LJ. Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer. *Surg Neurol* (1999) 51: pp. 6-11.
- Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T & Goggin PM. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. *Gut* (2005) 54: pp. 540-545.
- Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS & Jordan CT. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. *Blood* (2005) 105: pp. 4163-4169.
- Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, Becker MW, Bennett JM, Sullivan E, Lachowicz JL, Vaughan A, Sweeney CJ, Matthews W, Carroll M, Liesveld JL, Crooks PA & Jordan CT. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. *Blood* (2007) 110: pp. 4427-4435.
- H. L. Kindler, D. Niedzwiecki, D. Hollis, E. Ozafo, D. Schrag, H. Hurwitz, H. L. McLeod, M. F. Mulcahy, R. L. Schilsky, R. M. Goldberg, Cancer and Leukemia Group B. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). *Journal of Clinical Oncology*, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: A4508 (2007) : .

38. H. Riess, A. Helm, M. Niedergethmann, I. Schmidt-Wolf, M. Moik, C. Hammer, K. Zippel, K. Weigang-Köhler, M. Stauch, H. Oettle, Deutsche Krebsgesellschaft. A Randomised, Prospective, Multicenter, Phase III Trial of Gemcitabine, 5-Fluorouracil (5-FU), Folinic Acid vs. Gemcitabine alone in Patients with Advanced Pancreatic Cancer. *Journal of Clinical Oncology*, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4009 (2005) :
39. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. *BMC Cancer* (2008) 8: 82.
40. Heinemann V, Quetzsch D, Gieseler F, Gonnermann M, Schöneks H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowsky R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. *J Clin Oncol* (2006) 24: 3946-3952.
41. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne C, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. *J Clin Oncol* (2007) 25: 2212-2217.
42. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne C, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. *J Clin Oncol* (2007) 25: pp. 2212-2217.
43. Hilbig A. Src kinase and pancreatic cancer. *Recent Results Cancer Res* (2008) 177: pp. 179-185.
44. Holloway SE, Beck AW, Shivakumar L, Shih J, Fleming JB & Brekken RA. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. *Ann Surg Oncol* (2006) 13: pp. 1145-1155.
45. Holm E. Stoffwechsel und Ernährung bei Tumorerkrankungen. Analysen und Empfehlungen.. Georg Thieme Verlag, Stuttgart/New York (2007) : p. 69. [46] Hu W, Liu T, Xiong J & Wang C. Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. *Acta Pharmacol Sin* (2007) 28: pp. 1224-1230.
47. Ischenko I, Camaj P, Seeliger H, Kleespies A, Guba M, De Toni EN, Schwarz B, Graeb C, Eichhorn ME, Jauch K & Bruns CJ. Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling. *Oncogene* (2008) 27: pp. 7212-7222.
48. Jasinski P, Zwolak P, Terai K & Dudek AZ. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo. *Transl Res* (2008) 152: pp. 203-212.
49. Jeekel J. Author reply to: Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. *Ann Surg* (2006) 244: pp. 332-333.
50. Kalsner M & Ellenberg S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. *Arch Surg* (1985) 120: pp. 899-903.
51. Kindler H, Niedzwiecki D & Hollis DEA. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: A preliminary analysis of Cancer and Leukemia Group B. *J Clin Oncol* (2007) Vol. 25 (18S): p. A4508.
52. Klein S, Kinney J, Jeejeebhoy K, Alpers D, Hellerstein M, Murray M & Twomey P. Nutrition support in clinical practice: review of published data and recommendations for future research directions. Summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. *Am J Clin Nutr* (1997) 66: pp. 683-706.
53. Klinkenbijn JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A & Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. *Ann Surg* (1999) 230: p. 776-82; discussion 782-4.
54. Körber J, Pricelius S, Heidrich M & Müller MJ. Increased lipid utilization in weight losing and weight stable cancer patients with normal body weight. *Eur J Clin Nutr* (1999) 53: pp. 740-745.
55. Koshy MC, Landry JC, Cavanaugh SX, Fuller CD, Willett CG, Abrams RA, Hoffman JP & Thomas CRJ. A challenge to the therapeutic nihilism of ESPAC-1. *Int J Radiat Oncol Biol Phys* (2005) 61: pp. 965-966.
56. Kosuge T, Kiuchi T, Mukai K, Kakizoe T. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. *Jpn J Clin Oncol* (2006) 36: pp. 159-165.
57. Kulke MH, Blazskowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C & Fuchs CS. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. *J Clin Oncol* (2007) 25: pp. 4787-4792.
58. Kurahara H, Takao S, Maemura K, Shinchi H, Natsugoe S & Aikou T. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. *Clin Cancer Res* (2004) 10: pp. 8413-8420.
59. Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA & Bell DW. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. *Clin Cancer Res* (2006) 12: pp. 4283-4287.
60. Larboret C, Robert B, Navarro-Teulon I, Thèzenas S, Ladjemi M, Morisseau S, Campigna E, Bibeau F, Mach J, Pèlerin A & Azria D. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. *Clin Cancer Res* (2007) 13: pp. 3356-3362.
61. Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, Aderka D & Ben-Yosef R. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. *Cancer Invest* (2007) 25: pp. 411-418.
62. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF & Simeone DM. Identification of pancreatic cancer stem cells. *Cancer Res* (2007) 67: pp. 1030-1037.
63. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taieb J, Faroux R, Lepere C, de Gramont A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. *J Clin Oncol* (2005) 23: 3509-3516.
64. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J & Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* (2004) 350: pp. 2129-2139.
65. Macarulla T, Ramos FJ & Tabernero J. Aurora kinase family: a new target for anticancer drug. *Recent Patents Anticancer Drug Discov* (2008) 3: pp. 114-122.
66. Maples W, Stevenson J, Sumrall S, Naughton M, Kauh J & Schwartz J. Advanced Pancreatic Cancer: A multi-institutional trial with gemcitabine and thalidomide. , 2004.
67. Mariangeli F, Cicozzi A & Leonardi MEA. Use of strong opioids in advanced cancer pain: a randomized trial. *J Pain Symptom Manage* (1997) 14: pp. 99-117.
68. Marriott JB, Clarke IA, Czajka A, Dredge K, Childs K, Man H, Schafer P, Govinda S, Muller GW, Stirling DI & Dalglish AG. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. *Cancer Res* (2003) 63: pp. 593-599.
69. Martin LA & Hagen NA. Neuropathic pain in cancer patients: mechanisms, syndromes, and clinical controversies. *J Pain Symptom Manage* (1997) 14: pp. 99-117.
70. Moldawer LL & Copeland EM3. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. *Cancer* (1997) 79: pp. 1828-1839.

71. Moore MJ, GD, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W, National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol*. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23 (2007) : .
72. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* (2007) 25: pp. 1960-1966.
73. Morris SL, Beasley M & Leslie M. Chemotherapy for pancreatic cancer. *N Engl J Med* (2004) 350: p. 2713-5; author reply 2713-5.
74. Morton JP & Lewis BC. Shh signaling and pancreatic cancer: implications for therapy?. *Cell Cycle* (2007) 6: pp. 1553-1557.
75. Moses AWG, Slater C, Preston T, Barber MD & Fearon KCH. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. *Br J Cancer* (2004) 90: pp. 996-1002.
76. National Comprehensive Cancer Network.. NCCN Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma, v1.2007.. Available from URL: [http://www.nccn.org/professionals/physician\\_gls/PDF/pancreatic.pdf](http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf) [Accessed 2008 Dec 18]. (2007) : .
77. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner KJ, Huang P, Abbruzzese JL & McConkey DJ. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. *Cancer Res* (2005) 65: pp. 11658-11666.
78. Neoptolemos J. Clinical evidence does not support the use of adjuvant radiotherapy in pancreatic cancer.. *Nat Clin Pract Oncol* (2008) 5(8): p. 431.
79. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. *Lancet* (2001) 358: pp. 1576-1585.
80. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez-Cruz L, Lacaine F, Buckels J, Deakin M, Adab FA, Sutton R, Imrie I, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Büchler MW. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. *Ann Surg* (2001) 234: pp. 758-768.
81. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N Engl J Med* (2004) 350: pp. 1200-1210.
82. Neuhaus P, Riess H & Post S. CONKO-001: final results of the randomized, prospective, multicentre phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer.. *ASCO Annual Meeting Proceedings* (2008) 26 (18S): p. LBA4504.
83. Nitenberg G & Raynard B. Nutritional support of the cancer patient: issues and dilemmas. *Crit Rev Oncol Hematol* (2000) 34: pp. 137-168.
84. Oettle H, Goerke A & Kaiser AEA. Pankreaskarzinom. In: Seeber, S; Schütte, J. *Therapiekonzepte Onkologie.. Springer Verlag, Heidelberg, Germany* (2007) 5th Edition: pp. 13-33.
85. Oettle H, Pelzer U, Stieler J & Hilbig AEA. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO-003).. *J Clin Oncol* (2005) ASCO Annual Meeting Proceedings. Vol. 23(16S): p. A4031.
86. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein W, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B & Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. *JAMA* (2007) 297: pp. 267-277.
87. Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. *Ann Oncol* (2005) 16: 1639-1645.
88. Okada T, Sawada T, Osawa T, Adachi M & Kubota K. MK615 inhibits pancreatic cancer cell growth by dual inhibition of Aurora A and B kinases. *World J Gastroenterol* (2008) 14: pp. 1378-1382.
89. Orrevall Y, Tishelman C, Herrington MKMK & Permert J. The path from oral nutrition to home parenteral nutrition: a qualitative interview study of the experiences of advanced cancer patients and their families. *Clin Nutr* (2004) 23: pp. 1280-1287.
90. Palesty JA & Dudrick SJ. What we have learned about cachexia in gastrointestinal cancer. *Dig Dis* (2003) 21: pp. 198-213.
91. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R & Mahmoud R. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. *J Clin Oncol* (1998) 16: pp. 1588-1593.
92. Pelzer U. Second-line chemotherapy in advanced pancreatic cancer: Recent Results *Cancer Res* (2008) 177: pp. 61-64.
93. Pelzer U, Kubica K & Stieler JEA. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO-003 study.. *J Clin Oncol* (2008) 26 (May 20 suppl.): p. A4508.
94. Philip P, Benedetti J & Fenoglio-Preiser C. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study.. *J Clin Oncol* (2007) 25 (Jun 20 suppl.): p. LBA4509.
95. Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. *J Clin Oncol* 2007;25 (Jun 20 suppl.):LBA4509.
96. Pirlich M, Schütz T, Spachos T, Ertl S, Weiss ML, Lochs H & Plauth M. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. *Hepatology* (2000) 32: pp. 1208-1215.
97. Ravasco P, Monteiro-Grillo I, Marques Vidal P & Camilo ME. [Quality of life in gastrointestinal cancer: what is the impact of nutrition?]. *Acta Med Port* (2006) 19: pp. 189-196.
98. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG & Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. *JAMA* (2008) 299: pp. 1019-1026.
99. Robert F, Hurwitz H, Verschraegen C, Advani R, Berman C, Taverna P & Evan-chik M. Phase I trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients. , 2008. [100] Rocha Lima CM, Green MR, Rotche R, Miller WHJ, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. *J Clin Oncol* (2004) 22: 3776-3783.
101. Rojanala S, Han H, Muñoz RM, Browne W, Nagle R, Von Hoff DD & Bearss DJ. The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. *Mol Cancer Ther* (2004) 3: pp. 451-457.
102. Saeki H, Yanoma S, Takemiya S, Sugimasa Y, Akaike M, Yukawa N, Rino Y & Imada T. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. *Oncol Rep* (2007) 18: pp. 433-439.
103. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes TM, Maia C, Pasquariello T, Goldstein L, King T, Tsai JY & Kennedy T. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. *Cancer Invest* (2004) 22: pp. 706-712.
104. Safran H, Miner T, Resnick M, Dipetrillo T, McNulty B, Evans D, Joseph P, Plette A, Millis R, Sears D, Gutman N & Kennedy T. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. *Am J Clin Oncol* (2008) 31: pp. 140-144.
105. Sclabas GM, Fujioka S, Schmidt C, Evans DB & Chiao PJ. NF-kappaB in pancreatic cancer. *Int J Gastrointest Cancer* (2003) 33: pp. 15-26.

106. Sener SF, Fremgen A, Menck HR & Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. *J Am Coll Surg* (1999) 189: pp. 1-7.
107. Shafae Z, Schmidt H, Du W, Posner M & Weichselbaum R. Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells. *Cancer Chemother Pharmacol* (2006) 58: pp. 765-770.
108. Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, Lathia C, Petrenciu O & Moore MJ. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. *Clin Cancer Res* (2006) 12: pp. 144-151.
109. Sousa SF, Fernandes PA & Ramos MJ. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. *Curr Med Chem* (2008) 15: pp. 1478-1492.
110. Spano J, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Létourneau R, Bajetta E, Pithavala Y, Bycott P, Trask P, Liu K, Ricart AD, Kim S & Rixe O. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. *Lancet* (2008) 371: pp. 2101-2108.
111. Staats PS, Hekmat H, Sauter P & Lillemoe K. The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled study. *Pain Med* (2001) 2: pp. 28-34.
112. Stefaniak T, Basinski A, Vingerhoets A, Makarewicz W, Connor S, Kaska L, Stanek A, Kwiecinska B, Lachinski AJ & Sledzinski Z. A comparison of two invasive techniques in the management of intractable pain due to inoperable pancreatic cancer: neurolytic celiac plexus block and videothoroscopic splanchnicectomy. *Eur J Surg Oncol* (2005) 31: pp. 768-773.
113. Sultana A, Ghaneh P, Cunningham D, Starling N, Neoptolemos JP & Smith CT. Gemcitabine based combination chemotherapy in advanced pancreatic cancer: indirect comparison. *BMC Cancer* (2008) 8: p. 192.
114. Sultana A, Ghaneh P, Cunningham D, Starling N, Neoptolemos JP, Smith CT. Gemcitabine based combination chemotherapy in advanced pancreatic cancer: indirect comparison. *BMC Cancer* (2008) 8: 192.
115. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. *Cancer* (2002) 95: pp. 1685-1695.
116. Tang R, Wang S, Peng L, Wang S, Zhang M, Li Z, Zhang Z, Xiao Y & Zhang F. Expression of vascular endothelial growth factors A and C in human pancreatic cancer. *World J Gastroenterol* (2006) 12: pp. 280-286.
117. Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernández-del Castillo C, Yajnik V, Antoniu B, McMahon M, Warshaw AL & Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. *Nature* (2003) 425: pp. 851-856. [118] Thybusch-Bernhardt A, Beckmann S & Juhl H. Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. *Int J Surg Invest* (2001) 2: pp. 393-400.
119. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH & Gallick GE. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. *Am J Pathol* (2006) 168: pp. 962-972.
120. Uegaki K, Nio Y, Inoue Y, Minari Y, Sato Y, Song MM, Dong M & Tamura K. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. *Anticancer Res* (1997) 17: pp. 3841-3847.
121. Ulrich H, Pastores SM, Katz DP & Kvetan V. Parenteral use of medium-chain triglycerides: a reappraisal. *Nutrition* (1996) 12: pp. 231-238.
122. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y & Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. *J Clin Oncol* (2004) 22: pp. 1430-1438.
123. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. *J Clin Oncol* (2004) 22: 1430-1438.
124. Vervenne W, Humblet Y & Gill S. A randomized, double blind, placebo controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab to erlotinib and gemcitabine in patients with pancreatic cancer. *J Clin Oncol* (2008) 26 (May 20 suppl.): p. A4570.
125. Vervenne WBJ, Humblet Y, Gill S, et al. A randomized, double blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with pancreatic cancer. *J Clin Oncol* 2008;26 (May 20 Suppl.):A4570.
126. Xie D, Liang H, Wang Y, Guo S, Yang Q. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. *World J Gastroenterol* (2006) 12: 6973-6981.
127. Xie K, Wei D & Huang S. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. *Cytokine Growth Factor Rev* (2006) 17: pp. 147-156.
128. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. *Eur J Cancer* (2001) 37 Suppl 4: p. S3-8.
129. Yip-Schneider MT, Wu H, Njoku V, Ralstin M, Holcomb B, Crooks PA, Neelakantan S, Sweeney CJ & Schmidt CM. Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. *Pancreas* (2008) 37: p. e45-53.
130. Zech DF, Grond S, Lynch J, Hertel D & Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. *Pain* (1995) 63: pp. 65-76.